Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS-03 + FOLFOX/FOLFIRI + Bevacizumab in Metastatic Colorectal Cancer With RAS Mutation
NCT06936527Phase 2Enrolling by invitation
- Sponsor
- Fosun Pharma
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of XS-03 in colorectal cancer (CRC) (3 arms), sponsored by Fosun Pharma. Primary endpoints: Dose-limiting Toxicities, Maximum Tolerated Dose and 1 more. Started May 2025; status: enrolling by invitation.
02
Drugs
XS-03
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06936527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936527.